The association between serum uric acid levels (SUA) and cardiovascular (CV) disease has been extensively investigated in the last 3 decades. A large number of epidemiological studies have confirmed the unfavorable impact of increased serum concentrations of SUA on the future development of CV diseases in general population samples and in selected groups of patients [1–3]. The cutoff definitions for hyperuricemia were quite different among these studies, ranging from 6 to 10 mg/dL. Recently, in the framework of the URRAH study, we were able to identify the SUA cut-off values for incident CV events [4], lower than 6 mg/dl, identifying the level of SUA that might be used in clinical practice to improve stratification of subjects at greater risk of CV events, as recently suggested by 2018 European guidelines [5].
